Effect of cationic drugs on the transporting activity of human and rat OCT/Oct 1–3 in vitro and implications for drug–drug interactions

References

• Bauer LA, Black DJ, Lill JS, Garrison J, Raisys VA, Hooton TM. Levofloxacin and ciprofloxacin decrease procainamide and N-acetylprocainamide renal clearances. Antimicrobial Agents and Chemotherapy 2005; 49: 1649–1651
   PubMed Web of Science ®Google Scholar
• Bucchi A, Barbuti A, Baruscotti M, DiFrancesco D. Heart rate reduction via selective ‘funny’ channel blockers. Current Opinion in Pharmacology 2007; 7: 208–213
   PubMed Web of Science ®Google Scholar
• Ding R, Tayrouz Y, Riedel KD, Burhenne J, Weiss J, Mikus G, Haefeli WE. Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers. Clinical Pharmacology and Therapeutics 2004; 76: 73–84
   PubMed Web of Science ®Google Scholar
• Dudley AJ, Bleasby K, Brown CD. The organic cation transporter OCT2 mediates the uptake of beta-adrenoceptor antagonists across the apical membrane of renal LLC-PK(1) cell monolayers. British Journal of Pharmacology 2000; 131: 71–79
   PubMed Web of Science ®Google Scholar
• Ekaratanawong S, Anzai N, Jutabha P, Miyazaki H, Noshiro R, Takeda M, Kanai Y, Sophasan S, Endou H. Human organic anion transporter 4 is a renal apical organic anion/dicarboxylate exchanger in the proximal tubules. Journal of Pharmacological Sciences 2004; 94: 297–304
   PubMed Web of Science ®Google Scholar
• El-Sheikh AA, Van den Heuvel JJ, Koenderink JB, Russel FG. Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport. Journal of Pharmacology and Experimental Therapeutics 2007; 320: 229–235
   PubMed Web of Science ®Google Scholar
• Gorboulev V, Ulzheimer JC, Akhoundova A, Ulzheimer-Teuber I, Karbach U, Quester S, Baumann C, Lang F, Busch AE, Koepsell H. Cloning and characterization of two human polyspecific organic cation transporters. DNA and Cell Biology 1997; 16: 871–881
   PubMed Web of Science ®Google Scholar
• Grundemann D, Gorboulev V, Gambaryan S, Veyhl M, Koepsell H. Drug excretion mediated by a new prototype of polyspecific transporter. Nature 1994; 372: 549–552
   PubMed Web of Science ®Google Scholar
• Hardman JG, Molinoff PB, Ruddon RW, Gilman AG. Goodman & Gilman's: The pharmacological basis of therapeutics9th. McGraw-Hill, New York, NY 1996
   Google Scholar
• Indolfi C, Guth BD, Miura T, Miyazaki S, Schulz R, Ross J, Jr. Mechanisms of improved ischemic regional dysfunction by bradycardia. Studies on UL-FS 49 in swine. Circulation 1989; 80: 983–993
   PubMed Web of Science ®Google Scholar
• Jayasagar G, Krishna Kumar M, Chandrasekhar K, Madhusudan Rao C, Madhusudan Rao Y. Effect of cephalexin on the pharmacokinetics of metformin in healthy human volunteers. Drug Metabolism and Drug Interactions 2002; 19: 41–48
   PubMedGoogle Scholar
• Katoh M, Suzuyama N, Takeuchi T, Yoshitomi S, Asahi S, Yokoi T. Kinetic analyses for species differences in P-glycoprotein-mediated drug transport. Journal of Pharmaceutical Sciences 2006; 95: 2673–2683
   PubMed Web of Science ®Google Scholar
• Kekuda R, Prasad PD, Wu X, Wang H, Fei YJ, Leibach FH, Ganapathy V. Cloning and functional characterization of a potential-sensitive, polyspecific organic cation transporter (OCT3) most abundantly expressed in placenta. Journal of Biological Chemistry 1998; 273: 15971–15979
   PubMed Web of Science ®Google Scholar
• Lai MY, Jiang FM, Chung CH, Chen HC, Chao PD. Dose dependent effect of cimetidine on procainamide disposition in man. International Journal of Clinical Pharmacology, Therapy, and Toxicology 1988; 26: 118–121
   PubMed Web of Science ®Google Scholar
• Luckner P, Brandsch M. Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: Analysis of affinity constants and comparison with PEPT1. European Journal of Pharmaceutics and Biopharmaceutics 2005; 59: 17–24
   PubMed Web of Science ®Google Scholar
• Masuda S. Functional characteristics and pharmacokinetic significance of kidney-specific organic anion transporters, OAT-K1 and OAT-K2, in the urinary excretion of anionic drugs. Drug Metabolism and Pharmacokinetics 2003; 18: 91–103
   PubMedGoogle Scholar
• Motohashi H, Uwai Y, Hiramoto K, Okuda M, Inui K. Different transport properties between famotidine and cimetidine by human renal organic ion transporters (SLC22A). European Journal of Pharmacology 2004; 503: 25–30
   PubMed Web of Science ®Google Scholar
• Okuda M, Saito H, Urakami Y, Takano M, Inui K. cDNA cloning and functional expression of a novel rat kidney organic cation transporter, OCT2. Biochemical and Biophysical Research Communications 1996; 224: 500–507
   PubMed Web of Science ®Google Scholar
• Okuda M, Urakami Y, Saito H, Inui K. Molecular mechanisms of organic cation transport in OCT2-expressing Xenopus oocytes. Biochimica et Biophysica Acta 1999; 1417: 224–231
   PubMed Web of Science ®Google Scholar
• Ragueneau I, Laveille C, Jochemsen R, Resplandy G, Funck-Brentano C, Jaillon P. Pharmacokinetic–pharmacodynamic modeling of the effects of ivabradine, a direct sinus node inhibitor, on heart rate in healthy volunteers. Clinical Pharmacology and Therapeutics 1998; 64: 192–203
   PubMed Web of Science ®Google Scholar
• Roth W, Bauer E, Heinzel G, Cornelissen PJ, Van Tol RG, Jonkman JH, Zuiderwijk PB. Zatebradine: Pharmacokinetics of a novel heart-rate-lowering agent after intravenous infusion and oral administration to healthy subjects. Journal of Pharmaceutical Sciences 1993; 82: 99–106
   PubMed Web of Science ®Google Scholar
• Shu Y, Sheardown SA, Brown C, Owen RP, Zhang S, Castro RA, Ianculescu AG, Yue L, Lo JC, Burchard EG, et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. Journal of Clinical Investigation 2007; 117: 1422–1431
   PubMed Web of Science ®Google Scholar
• Somogyi A, Stockley C, Keal J, Rolan P, Bochner F. Reduction of metformin renal tubular secretion by cimetidine in man. British Journal of Clinical Pharmacology 1987; 23: 545–551
   PubMed Web of Science ®Google Scholar
• Takane H, Shikata E, Otsubo K, Higuchi S, Ieiri I. Polymorphism in human organic cation transporters and metformin action. Pharmacogenomics 2008; 9: 415–422
   PubMed Web of Science ®Google Scholar
• Umehara K, Iwatsubo T, Noguchi K, Kamimura H. Comparison of kinetic characteristics of inhibitory effects by biguanides and H2-blockers on the organic cation transporters-mediated transport between human (OCT) and rat (oct): Insight into the application to the development of drug candidates. Xenobiotica 2007a; 37: 618–634
   PubMed Web of Science ®Google Scholar
• Umehara KI, Iwatsubo T, Noguchi K, Kamimura H. Functional involvement of organic cation transporter1 (OCT1/Oct1) in the hepatic uptake of organic cations in humans and rats. Xenobiotica 2007b; 37: 818–831
   PubMed Web of Science ®Google Scholar
• Umehara KI, Iwatsubo T, Noguchi K, Kamimura H. Functional involvement of the organic cation transporter 2 (rOct2) in the renal uptake of organic cations in rats. Journal of International Medical Research 2008a; 36: 123–136
   PubMed Web of Science ®Google Scholar
• Umehara KI, Seta K, Sonoda T, Nakamura E, Noguchi K, Usui T, Kamimura H. Absorption, distribution, and excretion of YM758, a novel If channel inhibitor, in albino and non-albino rats. Xenobiotica 2008b; 38: 527–539
   PubMed Web of Science ®Google Scholar
• Van Crugten J, Bochner F, Keal J, Somogyi A. Selectivity of the cimetidine-induced alterations in the renal handling of organic substrates in humans. Studies with anionic, cationic and zwitterionic drugs. Journal of Pharmacology and Experimental Therapeutics 1986; 236: 481–487
   PubMed Web of Science ®Google Scholar
• Wang DS, Jonker JW, Kato Y, Kusuhara H, Schinkel AH, Sugiyama Y. Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. Journal of Pharmacology and Experimental Therapeutics 2002; 302: 510–515
   PubMed Web of Science ®Google Scholar
• Wang DS, Kusuhara H, Kato Y, Jonker JW, Schinkel AH, Sugiyama Y. Involvement of organic cation transporter 1 in the lactic acidosis caused by metformin. Molecular Pharmacology 2003; 63: 844–848
   PubMed Web of Science ®Google Scholar
• Wu X, Huang W, Ganapathy ME, Wang H, Kekuda R, Conway SJ, Leibach FH, Ganapathy V. Structure, function, and regional distribution of the organic cation transporter OCT3 in the kidney. AJP: Renal Physiology 2000; 279: F449–F458
   Google Scholar
• Wu X, Huang W, Prasad PD, Seth P, Rajan DP, Leibach FH, Chen J, Conway SJ, Ganapathy V. Functional characteristics and tissue distribution pattern of organic cation transporter 2 (OCTN2), an organic cation/carnitine transporter. Journal of Pharmacology and Experimental Therapeutics 1999; 290: 1482–1492
   PubMed Web of Science ®Google Scholar
• Yabuuchi H, Tamai I, Nezu J, Sakamoto K, Oku A, Shimane M, Sai Y, Tsuji A. Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations. Journal of Pharmacology and Experimental Therapeutics 1999; 289: 768–773
   PubMed Web of Science ®Google Scholar
• Yokoo S, Yonezawa A, Masuda S, Fukatsu A, Katsura T, Inui K. Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity. Biochemical Pharmacology 2007; 74: 477–487
   PubMed Web of Science ®Google Scholar
• Zhang L, Dresser MJ, Gray AT, Yost SC, Terashita S, Giacomini KM. Cloning and functional expression of a human liver organic cation transporter. Molecular Pharmacology 1997; 51: 913–921
   PubMed Web of Science ®Google Scholar
• Zhou SF, Xue CC, Yu XQ, Li C, Wang G. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Therapeutic Drug Monitoring 2007; 29: 687–710
   PubMed Web of Science ®Google Scholar